Breast Cancer in Adolescents and Young Adults: A Review With a Focus on Biology

Authors:
Jill R. Tichy From the University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and Dana-Farber Cancer Institute, Boston, Massachusetts.

Search for other papers by Jill R. Tichy in
Current site
Google Scholar
PubMed Close
 MD
,
Elgene Lim From the University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and Dana-Farber Cancer Institute, Boston, Massachusetts.

Search for other papers by Elgene Lim in
Current site
Google Scholar
PubMed Close
 MD, PhD
, and
Carey K. Anders From the University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and Dana-Farber Cancer Institute, Boston, Massachusetts.

Search for other papers by Carey K. Anders in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 11: Issue 9
Online Publication Date:
Sep 2013
DOI:
https://doi.org/10.6004/jnccn.2013.0128
Restricted access

Breast cancer is a substantial contributor to adolescent and young adult (AYA) malignancies, defined as a diagnosis of cancer between the ages of 15 and 39. In the United States, 6.6% of breast cancer cases are diagnosed among women younger than 40 years. When breast cancer occurs in AYAs, it typically has a worse prognosis and more-aggressive phenotype; higher proportions of high-grade and later-stage tumors; lower estrogen receptor positivity; and, in some studies, higher expression of HER2. Age-specific differences in the biology of AYA breast cancer have been explored in large-scale genomic studies with mixed results. Although some studies suggest that AYA breast cancer has a unique biology, others have shown that its aggressive nature is the result of higher frequencies of aggressive breast cancer subtypes among younger patients. More recently, stromal-related gene signatures have shown prognostic significance in AYA breast cancer, suggesting that differences in microenvironment may account for age-specific differences in breast cancer behavior. Although general principles for selecting cytotoxic and targeted agents are similar between AYAs and the general breast cancer population, endocrine therapy choices in the adjuvant and metastatic settings vary by pre- and postmenopausal status. The role of ovarian suppression remains controversial and is reviewed. The AYA population is a unique group of patients who need individualized care, including considerations of hereditary breast cancer predispositions, future fertility, and the effect of therapy on immediate and long-term quality of life, all of which require coordinated multidisciplinary care. This article addresses the epidemiology, genetics, and management of breast cancer in AYA women and highlights unique medical issues important to this population.

Correspondence: Carey K. Anders, MD, University of North Carolina at Chapel Hill, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599-7305. E-mail: carey_anders@med.unc.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Closing the gap: research and cancer care imperatives for adolescents and young adults with cancer; report of the Adolescent and Young Adult Oncology Progress Review Group. Available at: http://planning.cancer.gov/library/AYAO_PRG_Report_2006_FINAL.pdf. Accessed July 30, 2013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    National Cancer Institute. A Snapshot of Adolescent and Young Adult Cancers. Available at: http://www.cancer.gov/researchandfunding/snapshots/adolescent-young-adult. Accessed July 30, 2013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Bleyer A, Barr R, Hayes-Lattin B et al.. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288–298.

  • 4.

    Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res 2010;12:212.

  • 5.

    Gnerlich JL, Deshpande AD, Jeffe DB et al.. Elevated breast cancer mortality in young women (< 40 years) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg 2009;208:341–347.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Coombs NJ, Cronin KA, Taylor RJ et al.. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control 2010;21:83–90.

  • 7.

    Anders CK, Johnson R, Litton J et al.. Breast cancer before age 40 years. Semin Oncol 2009;36:237–249.

  • 8.

    Go RS, Gundrum JD. Cancer in the adolescent and young adult (AYA) population in the United States: current statistics and projections [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 6072.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Ferlay J, Shin H, Bray F et al.. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr. Accessed July 30, 2013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893–1907.

  • 11.

    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–2150.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Adami HO, Malker B, Holmberg L et al.. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559.

  • 13.

    Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997;33:425–428.

  • 14.

    El Saghir NS, Seoud M, Khalil MK et al.. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.

  • 15.

    Nixon AJ, Neuberg D, Hayes DF et al.. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12:888–894.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Kollias J, Elston C, Ellis I et al.. Early-onset breast cancer— histopathological and prognostic considerations. Br J Cancer 1997;75:1318–1323.

  • 17.

    Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;309:800–805.

  • 18.

    Colleoni M, Rotmensz N, Robertson C et al.. Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002;13:273–279.

  • 19.

    Anders CK, Hsu DS, Broadwater G et al.. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26:3324–3330.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Azim HA Jr, Michiels S, Bedard PL et al.. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012;18:1341–1351.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Perou CM, Sørlie T, Eisen MB et al.. Molecular portraits of human breast tumours. Nature 2000;406:747–752.

  • 22.

    Sørlie T, Tibshirani R, Parker J et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418–8423.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    The Cancer Genome Atlas Network. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.

  • 24.

    Anders CK, Fan C, Parker JS et al.. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011;29:e18–20.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Parker JS, Mullins M, Cheang MC et al.. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160–1167.

  • 26.

    Lim E, Vaillant F, Wu D et al.. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907–913.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Goodwin PJ. Management of familial breast cancer risk. Breast Cancer Res Treat 2000;62:19–33.

  • 28.

    Brose MS, Rebbeck TR, Calzone KA et al.. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365–1372.

  • 29.

    Malone KE, Daling JR, Neal C et al.. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1393–1402.

  • 30.

    Atchley DP, Albarracin CT, Lopez A et al.. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282–4288.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Gonzalez-Angulo AM, Timms KM, Liu S et al.. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082–1089.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Bane AL, Beck JC, Bleiweiss I et al.. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007;31:121–128.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Carey LA. American Society of Clinical Oncology: Self-Evaluation Program: Breast Cancer. ASCO Self Evaluation Program (ASCO-SEP): Alexandria, VA: American Society of Clinical Oncology; 2010:113.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Kleihues P, Schäuble B, Zur Hausen A et al.. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997;150:1–13.

  • 35.

    Masciari S, Dillon DA, Rath M et al.. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012;133:1125–1130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al.. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908–913.

  • 37.

    Wilson JRF, Bateman AC, Hanson H et al.. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771–774.

  • 38.

    Langerod A, Zhao H, Borgan O et al.. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9:R30.

  • 39.

    Eng C. PTEN Hamartoma Tumor Syndrome (PHTS). Available at: http://www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed July 30, 2013.

  • 40.

    Daly MB, Axilbund JE, Buys SS et al.. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 3, 2013. Available at: NCCN.org. Accessed July 30, 2013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811–1814.

  • 42.

    Swerdlow AJ, Schoemaker MJ, Higgins CD et al.. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005;97:1204–1210.

  • 43.

    Theriault RL, Carlson RW, Allred C et al.. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. Version 3, 2013. Available at: NCCN.org. Accessed July 30, 2013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1996;348:1189–1196.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Gnant M, Mlineritsch B, Schippinger W et al.. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679–691.

  • 46.

    Roché H, Kerbrat P, Bonneterre J et al.. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 2006;17:1221–1227.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Klijn J, Blamey R, Boccardo F et al.. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343–353.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Cuzick J, Ambroisine L, Davidson N et al.. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711–1723.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Carlson RW, Theriault R, Schurman CM et al.. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010;28:3917–3921.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Loible S, Jackisch C, Gade S et al.. Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 2012;72(Suppl 24):33s.

  • 51.

    Lee SJ, Schover LR, Partridge AH et al.. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–2931.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Ganz PA, Guadagnoli E, Landrum MB et al.. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003;21:4027–4033.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–1729.

  • 54.

    Ganz PA, Desmond KA, Leedham B et al.. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39–49.

  • 55.

    Partridge AH, Gelber S, Peppercorn J et al.. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174–4183.

  • 56.

    The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte preservation: a guideline. Fertil Steril 2013;99:37–43.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Del Mastro L, Boni L, Michelotti A et al.. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. JAMA 2011;306:269–276.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Munster PN, Moore AP, Ismail-Khan R et al.. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533–538.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2013 by the National Comprehensive Cancer Network 2013
Page Numbers:
10
Article Category:
Research Article
Received:
10 Jan 2013
Accepted:
09 May 2013
Print Publication Date:
01 Sep 2013
Online Publication Date:
Sep 2013

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 8218 3152 132
PDF Downloads 5525 1073 46
EPUB Downloads 0 0 0